All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-09-26T08:40:08.000Z

Phase II study finds entospletinib has limited activity in patients with R/R DLBCL

Sep 26, 2018
Share:

Bookmark this article

A study by John Burke, Rocky Mountain Cancer Centers, the US oncology network, Aurora, Colorado, and colleagues was published in Clinical Lymphoma, Myeloma & Leukemia on the findings from the phase II open-label study of entospletinib monotherapy (GS-9973) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Entospletinib is an oral, selective spleen tyrosine kinase inhibitor. A previous study assessed the safety, tolerability and efficacy of entospletinib with R/R hematologic malignancies (NCT01799889) however, only the results from chronic lymphocytic leukemia (CLL) cohort have been reported thus far.

Study Overview

  • N = 43 patients with R/R DLBCL were included in the study and treated with a pre-determined recommended dose of 800 mg entospletinib twice daily
    • 65% of patients were male and the median age was 68 (range, 27–89)
    • The median number of prior lines of therapy was 2 (range, 1–7)
    • 42% of patients had germinal center B-cell (GCB) subtype and 39% had non-GCB subtype
  • The primary endpoint of the study was progression-free survival at 16 weeks assessed by an independent review committee (IRC)
  • The secondary endpoints included; safety, objective response rate (ORR), duration of response (DOR) and time-to-response assessed by an IRC

Key Findings

  • The 16-week PFS rate was 3.6% (95% CI, 0.3–15.3%)
  • The median PFS was 1.5 months (95% CI, 1.1–1.7 months)
  • The most frequent adverse events (AEs) Grade ≥3 included: lymphocytopenia (37%), hyponatremia (12%), increased ALT (12%), fatigue (9%) and diarrhea (9%)
  • 10 patients died of disease progression (n = 7) and 3 died of causes considered unrelated to study drug (septic shock, acidosis, and respiratory failure)

The authors concluded that the safety findings for the DLBCL cohort were similar to the other cohorts in the study. As monotherapy, entospletinib demonstrated limited activity in patients with R/R DLBCL. The authors suggested that there may be a need for clinical trials where entospletinib is used in combination therapy.

  1. Burke JM. Et al. An open-label, phase II trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in diffuse large B-cell lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 2018 Jun 6. pii: S2152-2650(18)30238-6. doi: 10.1016/j.clml.2018.05.022. [Epub ahead of print]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox